Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice

Journal of Pharmacological Sciences

Volumn 133, Issue 4, 2017, Pages 214-222

  Takei, Kenta ^a   Nakagawa, Yoshimi ^a   Wang, Yunong ^a   Han, Song iee ^a   Satoh, Aoi ^a   Sekiya, Motohiro ^a   Matsuzaka, Takashi ^a   Shimano, Hitoshi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Cholesterol absorption; HDL cholesterol; PPAR ; SPPARM

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G5; CHOLESTEROL; CYCLOPHILIN; FIBROBLAST GROWTH FACTOR 21; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PEMAFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; BENZOXAZOLE DERIVATIVE; BUTYRIC ACID DERIVATIVE; FATTY ACID; K-877 COMPOUND; LOW DENSITY LIPOPROTEIN RECEPTOR;

ABCA1 GENE; ABCG5 GENE; ACOX1 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOA1 GENE; APOA5 GENE; APOB GENE; APOC2 GENE; APOC3 GENE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CPT1 ALPHA; CREB3L3 GENE; CYCLOPHILIN GENE; DRUG EFFECT; DRUG STRUCTURE; FATTY ACID OXIDATION; FGF21 GENE; GENE; GENE EXPRESSION; GENE TARGETING; HYPERLIPIDEMIA; LIPID METABOLISM; LIVER FUNCTION; LOW DENSITY LIPOPROTEIN RECEPTOR KO MOUSE; LXR ALPHA; LXR BETA; MALE; MOUSE; NONHUMAN; NPC1L1 GENE; SMALL INTESTINE; TRIACYLGLYCEROL BLOOD LEVEL; AGONISTS; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENE INACTIVATION; GENETICS; HYPERLIPIDEMIAS; INTESTINE ABSORPTION; KNOCKOUT MOUSE; LIVER; METABOLISM; MOLECULARLY TARGETED THERAPY; OXIDATION REDUCTION REACTION;

ANIMALS; ATHEROSCLEROSIS; BENZOXAZOLES; BUTYRATES; CHOLESTEROL; DISEASE MODELS, ANIMAL; FATTY ACIDS; GENE EXPRESSION; GENE KNOCKOUT TECHNIQUES; HYPERLIPIDEMIAS; INTESTINAL ABSORPTION; INTESTINE, SMALL; LIPID METABOLISM; LIVER; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; OXIDATION-REDUCTION; PPAR ALPHA; RECEPTORS, LDL;

EID: 85016452385     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1016/j.jphs.2017.02.003     Document Type: Article

References (44)

1. 1 Diabetes Atherosclerosis Intervention Study Investigators, Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357 (2001), 905–910.
2. 2 Bloomfield Rubins, H., Davenport, J., Babikian, V., et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 103 (2001), 2828–2833.
3. 3 Rubins, H.B., Robins, S.J., Collins, D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999), 410–418.
4. 4 Tanne, D., Koren-Morag, N., Graff, E., Goldbourt, U., Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor. Circulation 104 (2001), 2892–2897.
5. 5 The Bezafibrate Infarction Prevention (BIP) Study, Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 102 (2000), 21–27.
6. 6 Francis, G.A., Knopp, R.H., Oram, J.F., Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier Disease. J Clin Investig 96 (1995), 78–87.
7. 7 Schmitz, G., Langmann, T., Structure, function and regulation of the ABC1 gene product. Curr Opin Lipidol 12 (2001), 129–140.
8. 8 Parks, J.S., Chung, S., Shelness, G.S., Hepatic ABC transporters and triglyceride metabolism. Curr Opin Lipidol 23 (2012), 196–200.
9. 9 Timmins, J.M., Lee, J.Y., Boudyguina, E., et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Investig 115 (2005), 1333–1342.
10. 10 Brunham, L.R., Kruit, J.K., Iqbal, J., et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Investig 116 (2006), 1052–1062.
11. 11 Kesaniemi, Y.A., Miettinen, T.A., Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population. Eur J Clin Investig 17 (1987), 391–395.
12. 12 Wilson, M.D., Rudel, L.L., Review of cholesterol absorption with emphasis on dietary and biliary cholesterol. J Lipid Res 35 (1994), 943–955.
13. 13 McGill, H.C. Jr., The relationship of dietary cholesterol to serum cholesterol concentration and to atherosclerosis in man. Am J Clin Nutr 32 (1979), 2664–2702.
14. 14 Dawson, P.A., Rudel, L.L., Intestinal cholesterol absorption. Curr Opin Lipidol 10 (1999), 315–320.
15. 15 Davis, H.R. Jr., Zhu, L.J., Hoos, L.M., et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 279 (2004), 33586–33592.
16. 16 Altmann, S.W., Davis, H.R. Jr., Zhu, L.J., et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303 (2004), 1201–1204.
17. 17 Cohen, J.C., Pertsemlidis, A., Fahmi, S., et al. Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci U S A 103 (2006), 1810–1815.
18. 18 Knight, B.L., Patel, D.D., Humphreys, S.M., Wiggins, D., Gibbons, G.F., Inhibition of cholesterol absorption associated with a PPAR alpha-dependent increase in ABC binding cassette transporter A1 in mice. J Lipid Res 44 (2003), 2049–2058.
19. 19 McNamara, D.J., Davidson, N.O., Samuel, P., Ahrens, E.H. Jr., Cholesterol absorption in man: effect of administration of clofibrate and/or cholestyramine. J Lipid Res 21 (1980), 1058–1064.
20. 20 Umeda, Y., Kako, Y., Mizutani, K., et al. Inhibitory action of gemfibrozil on cholesterol absorption in rat intestine. J Lipid Res 42 (2001), 1214–1219.
21. 21 Vanhanen, H.T., Miettinen, T.A., Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination. Atherosclerosis 115 (1995), 135–146.
22. 22 Valasek, M.A., Clarke, S.L., Repa, J.J., Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse. J Lipid Res 48 (2007), 2725–2735.
23. 23 Raza-Iqbal, S., Tanaka, T., Anai, M., et al. Transcriptome analysis of K-877 (a novel selective PPARalpha modulator (SPPARMalpha))-regulated genes in primary human hepatocytes and the mouse liver. J Atheroscler Thromb 22 (2015), 754–772.
24. 24 Fruchart, J.C., Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMalpha): the next generation of peroxisome proliferator-activated receptor alpha-agonists. Cardiovasc Diabetol, 12, 2013, 82.
25. 25 Nakagawa, Y., Shimano, H., Yoshikawa, T., et al. TFE3 transcriptionally activates hepatic IRS-2, participates in insulin signaling and ameliorates diabetes. Nat Med 12 (2006), 107–113.
26. 26 Kobayashi, M., Ikegami, H., Fujisawa, T., et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 56 (2007), 239–247.
27. 27 Folch, J., Lees, M., Sloane Stanley, G.H., A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226 (1957), 497–509.
28. 28 Lee, J.H., Giannikopoulos, P., Duncan, S.A., et al. The transcription factor cyclic AMP-responsive element-binding protein H regulates triglyceride metabolism. Nat Med 17 (2011), 812–815.
29. 29 Fujimoto, Y., Nakagawa, Y., Satoh, A., et al. TFE3 controls lipid metabolism in adipose tissue of male mice by suppressing lipolysis and thermogenesis. Endocrinology 154 (2013), 3577–3588.
30. 30 Hennuyer, N., Duplan, I., Paquet, C., et al. The novel selective PPARalpha modulator (SPPARMalpha) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. Atherosclerosis 249 (2016), 200–208.
31. 31 Ishibashi, S., Yamashita, S., Arai, H., et al. Effects of K-877, a novel selective PPARalpha modulator (SPPARMalpha), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis 249 (2016), 36–43.
32. 32 Montagner, A., Polizzi, A., Fouche, E., et al. Liver PPARalpha is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Gut 65 (2016), 1202–1214.
33. 33 Kimura, R., Takahashi, N., Murota, K., et al. Activation of peroxisome proliferator-activated receptor-alpha (PPARalpha) suppresses postprandial lipidemia through fatty acid oxidation in enterocytes. Biochem Biophys Res Commun 410 (2011), 1–6.
34. 34 Schoonjans, K., Peinado-Onsurbe, J., Lefebvre, A.M., et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 15 (1996), 5336–5348.
35. 35 Staels, B., Vu-Dac, N., Kosykh, V.A., et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Investig 95 (1995), 705–712.
36. 36 Badman, M.K., Pissios, P., Kennedy, A.R., Koukos, G., Flier, J.S., Maratos-Flier, E., Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5 (2007), 426–437.
37. 37 Inagaki, T., Dutchak, P., Zhao, G., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 5 (2007), 415–425.
38. 38 Iwayanagi, Y., Takada, T., Tomura, F., et al. Human NPC1L1 expression is positively regulated by PPARalpha. Pharm Res 28 (2011), 405–412.
39. 39 Kikuchi, T., Orihara, K., Oikawa, F., et al. Intestinal CREBH overexpression prevents high-cholesterol diet-induced hypercholesterolemia by reducing Npc1l1 expression. Mol Metab 5 (2016), 1092–1102.
40. 40 Kannisto, K., Gafvels, M., Jiang, Z.Y., et al. LXR driven induction of HDL-cholesterol is independent of intestinal cholesterol absorption and ABCA1 protein expression. Lipids 49 (2014), 71–83.
41. 41 Duez, H., Chao, Y.S., Hernandez, M., et al. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem 277 (2002), 48051–48057.
42. 42 Li, L., Beauchamp, M.C., Renier, G., Peroxisome proliferator-activated receptor alpha and gamma agonists upregulate human macrophage lipoprotein lipase expression. Atherosclerosis 165 (2002), 101–110.
43. 43 Iqbal, J., Parks, J.S., Hussain, M.M., Lipid absorption defects in intestine-specific microsomal triglyceride transfer protein and ATP-binding cassette transporter A1-deficient mice. J Biol Chem 288 (2013), 30432–30444.
44. 44 Laffitte, B.A., Joseph, S.B., Walczak, R., et al. Autoregulation of the human liver X receptor alpha promoter. Mol Cell Biol 21 (2001), 7558–7568.